Trials / Conditions / Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Recurrent Fallopian Tube Clear Cell Adenocarcinoma
4 registered clinical trials studyying Recurrent Fallopian Tube Clear Cell Adenocarcinoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Withdrawn | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without B NCT06393751 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity NCT05920798 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R NCT02839707 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |